Antibiotic Resistance of Helicobacter pylori in Turkey: A Systematic Review and Meta-Analysis

被引:7
作者
Ayas, Meltem [1 ]
Gurol, Yesim [2 ]
机构
[1] Acibadem Mehmet Ali Aydinlar Univ, Inst Hlth Sci, Dept Med Biotechnol, Kayisdagi St 32, TR-34752 Istanbul, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Med Microbiol, Istanbul, Turkiye
关键词
Helicobacter pylori; antibiotic resistance; Turkey; meta-analysis; IN-SITU HYBRIDIZATION; 23S RIBOSOMAL-RNA; CLARITHROMYCIN RESISTANCE; POINT MUTATIONS; TRIPLE THERAPY; INFECTION; ERADICATION; PREVALENCE; SUSCEPTIBILITY; AMOXICILLIN;
D O I
10.1089/mdr.2022.0146
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Turkey presents both a high prevalence of Helicobacter pylori infection and high prevalence of antibiotic resistance. In this study, we aimed to summarize recent data on H. pylori antibiotic resistance rates in this nation. After conducting searches in two national and international databases (ULAKBIM, EKUAL, and PubMed), a systematic review was conducted. A total of 197 original articles on antibiotic resistance of H. pylori in Turkey were collected. After screening for inclusion and exclusion criteria, to evaluate the H. pylori antibiotic resistance for the period 2005-2020, 20 eligible articles were included in the meta-analysis. Data analysis was performed using MedCalc 12.7.0. The number of isolated H. pylori strains in each study was weighted, and pooled proportion analysis was performed. This review included 20 Turkish studies, including 1,556 H. pylori strains. The overall resistance rates were as follows: clarithromycin (CLA), 26.7% (95% confidence interval [CI]: 20.5-33.5); metronidazole (MTZ), 28.4% (95% CI: 19.7-38.1); levofloxacin (LVX), 19.6% (95% CI: 9.9-31.7); tetracycline (TET), 0.7% (95% CI: 0.1-1.8); and amoxicillin (AMO), 1.3% (95% CI: 0.3-3.1). The reported results showed that Turkish H. pylori isolates are highly resistant to CLA, MTZ, and LVX, while exhibiting a low level of resistance toward AMO and TET.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 42 条
[1]  
[Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
[2]   Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition [J].
Asaka, Masahiro ;
Kato, Mototsugu ;
Takahashi, Shin-ichi ;
Fukuda, Yoshihiro ;
Sugiyama, Toshiro ;
Ota, Hiroyoshi ;
Uemura, Naomi ;
Murakami, Kazunari ;
Satoh, Kiichi ;
Sugano, Kentaro .
HELICOBACTER, 2010, 15 (01) :1-20
[3]   Helicobacter pyloriinfection in hemodialysis patients: Susceptibility to amoxicillin and clarithromycin [J].
Aydemir, Selim ;
Boyacioglu, Sedat ;
Gur, Gurden ;
Demirbilek, Muge ;
Can, Fusun Kamber ;
Korkmaz, Murat ;
Yilmaz, Ugur .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (06) :842-845
[4]  
Baglan PH, 2006, J MICROBIOL, V44, P409
[5]   Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco) [J].
Benajah, Dafr Allah ;
Lahbabi, Mounia ;
Alaoui, Samia ;
El Rhazi, Karima ;
El Abkari, Mohammed ;
Nejjari, Chakib ;
Amarti, Afaf ;
Bennani, Bahia ;
Mahmoud, Mustapha ;
Ibrahimi, Sidi Adil .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (05) :519-526
[6]  
Çagan-Appak Y, 2016, TURKISH J PEDIATR, V58, P371, DOI 10.24953/turkjped.2016.04.004
[7]  
Caliskan R, 2015, REV SOC BRAS MED TRO, V48, P278
[8]   Diagnosis of Helicobacter pylori infection and determination of clarithromycin resistance by fluorescence in situ hybridization from formalin-fixed, paraffin-embedded gastric biopsy specimens [J].
Can, F ;
Yilmaz, Z ;
Demirbilek, M ;
Bilezikci, B ;
Kunefeci, G ;
Atac, FB ;
Selcuk, H ;
Arslan, H ;
Boyacioglu, S ;
Sahin, FI .
CANADIAN JOURNAL OF MICROBIOLOGY, 2005, 51 (07) :569-573
[9]   Clarithromycin Resistance and Efficacy of Clarithromycin-Containing Triple Eradication Therapy for Helicobacter pylori Infection in Type 2 Diabetes Mellitus Patients [J].
Demir, Mehmet ;
Gokturk, Huseyin Savas ;
Ozturk, Nevin Akcaer ;
Arslan, Hande ;
Serin, Ender ;
Yilmaz, Ugur .
SOUTHERN MEDICAL JOURNAL, 2009, 102 (11) :1116-1120
[10]  
Ekin N., 2021, J HARRAN U MED FACUL, V18, P101